Our pioneering scientists have focused on understanding the properties of human birth tissue—ultimately identifying HC-HA/PTX3 as a key orchestrator in healing in the human fetal environment.1-5
BioTissue’s initial research and development efforts were focused on the development of its cornerstone cryopreservation technology – CryoTek. The CryoTek process is a proprietary tissue-processing method that preserves the innate biological and structural integrity of the natural placental tissue and therefore preserves and delivers the anti-inflammatory, anti-scarring, and anti-angiogenesis properties of that matrix. In particular, the CryoTek process is the ONLY method proven to effectively retain the Heavy Chain Hyaluronic Acid/Pentraxin3 (HC-HA/PTX3) complex, which has been demonstrated to orchestrate an environment that promotes regenerative healing. CryoTek-processed tissues are also the only available placental allografts that have been shown to be equivalent to fresh placental tissue and superior to other available placental allografts that are provided in a dehydrated state.
The clinical benefits of the CryoTek process have been demonstrated in more than 300 peer-reviewed publications. By devitalizing the resident living cells, CryoTek minimizes the risk of an immune reaction while preserving key components of the extracellular matrix: 6-8
- Collagen (types I, III, IV, V and VI)
- Hyaluronic Acid
- Growth Factors
- HC-HA/PTX3 (immuno-signaling complex)
Cryopreserved amniotic membrane has been demonstrated to promote critical healing actions:
- Modulate inflammation to orchestrate a regenerative healing environment
- Decrease scarring
Consistent with our mission of continued innovation, BioTissue commercialized allografts preserved via our proprietary SteriTek preservation process. This unique technology yields a shelf-stable product while maintaining the natural hydration of the tissue. The tissue is cleaned, processed and packaged consistent with the CryoTek cryopreservation process to maintain the structural and biological integrity of the natural tissue, but is then terminally sterilized using gamma irradiation, yielding a fully hydrated product that can be stored at controlled room temperature.
*BioTissue Inc. has published conceptual research elucidating the underlying science of birth tissue, amniotic membrane. This breakthrough research suggests that the HC-HA/PTX3 Complex plays an important role in facilitating an ideal environment suitable to manage healing across a range of surgical and wound management applications. This is disclosed in BioTissue’s regulatory applications to the FDA. Each surgeon must evaluate the appropriateness of the techniques based on his or her own medical training and expertise. Many variables including patient pathology, anatomy, and surgical techniques may influence procedural outcomes. While these clinical experiences are valid, the results are not necessarily typical, indicative or representative of all procedures in which BioTissue’s products are utilized.